Patents by Inventor Orit Foord

Orit Foord has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BICISTRONIC INHIBITORY CHIMERIC ANTIGEN RECEPTOR (ICAR)/ACTIVATING CHIMERIC ANTIGEN RECEPTOR (ACAR) CONSTRUCTS FOR USE IN CANCER THERAPIES
    Publication number: 20240016839
    Abstract: The invention relates to the field of cancer immunotherapy by employing bicistronic inhibitory chimeric antigen receptor (iCAR)/activating chimeric antigen receptor (aCAR) constructs for use in cancer treatment therapies.
    Type: Application
    Filed: September 7, 2021
    Publication date: January 18, 2024
    Inventors: Rick Kendall, Frank Calzone, Orit Foord, Gregor B. Adams, Tanya Kim, David Bassan, Jason Yi, Adi Sharbi-Yunger
  • METHODS FOR SELECTIVE EXPANSION OF DELTA-3 GAMMA DELTA T-CELL POPULATIONS AND COMPOSITIONS THEREOF
    Publication number: 20230257462
    Abstract: The present application is directed to agents that bind an epitope specific to a ?3 ?? TCR. Such agents can be, but are not limited to, an antibody or fragment thereof. Also described herein are methods for using the agents, e.g., to expand or selectively expand ?3 ?? T cells. Also described herein are methods of using expanded ?3 ?? T cells for treatment of a subject in need thereof.
    Type: Application
    Filed: November 15, 2018
    Publication date: August 17, 2023
    Inventors: Aya Jakobovits, Daulet Kadyl Satpayev, Orit Foord, Yifeng Frank Jing, Hui Shao, Jason Michael Romero, Mary Michael Brodey, Matthew Ian Hoopes
  • METHODS FOR EXPANDING GAMMA DELTA T-CELL POPULATIONS WITH MULTIVALENT AGENTS AND COMPOSITIONS THEREOF
    Publication number: 20230009275
    Abstract: The present invention relates to methods employing soluble multivalent activating agents for the selective in vitro and ex vivo activation and expansion ?? T-cell population(s), including specific ?? T-cell subpopulation(s) of interest and admixtures thereof, and methods for using the same for therapeutic purposes. Methods and compositions of the disclosure are useful in the treatment of various cancers, infectious diseases, and immune disorders.
    Type: Application
    Filed: December 3, 2020
    Publication date: January 12, 2023
    Inventors: Aya JAKOBOVITS, Daulet SATPAYEV, Orit FOORD, Yifeng Frank JING, Hui SHAO, Arun BHAT
  • METHODS FOR SELECTIVE EXPANSION OF GAMMA DELTA T-CELL POPULATIONS AND COMPOSITIONS THEREOF
    Publication number: 20220372439
    Abstract: The present invention relates to methods for the selective expansion of ?? T-cell population(s), compositions and admixtures thereof and methods for using the same as a therapeutic. Non-engineered and engineered, enriched ?? T-cell populations of the disclosure are useful in the treatment of various cancers, infectious diseases, and immune disorders.
    Type: Application
    Filed: April 11, 2022
    Publication date: November 24, 2022
    Inventors: Aya Jakobovits, Orit Foord, Andy An-deh Lin, Marianne Theresa Santaguida, Radhika Chetan Desai, Yifeng Frank Jing, Daulet Kadyl Satpayev, Yan Li
  • Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
    Patent number: 11492411
    Abstract: The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.
    Type: Grant
    Filed: November 4, 2019
    Date of Patent: November 8, 2022
    Assignee: Amgen Fremont Inc.
    Inventors: Richard F. Weber, Xiao Feng, Orit Foord, Larry L. Green, Jean M. Gudas, Bruce A. Keyt, Ying Liu, Palaniswami Rathanaswami, Robert Raya, Xiao Dong Yang, Jose R. F. Corvalan, Ian Foltz, Xiao-Chi Jia, Jaspal Singh Kang, Chadwick Terence King, Scott L. Klakamp, Qiaojuan Jane Su
  • Antibodies capable of binding HLA-A2/TyrD in an HLA restricted manner and uses thereof
    Patent number: 11485785
    Abstract: Antibodies capable of binding HLA-A2/Tyrosinase (TyrD) in an HLA restricted manner are provided. Specifically, the antibodies are capable of binding HLA-A2/TyrD369-377 in an HLA restricted manner. Further provided are complementary determining region (CDR) sequences of heavy chain and light chain of antibodies, and methods of using the antibodies for the treatment of cancer.
    Type: Grant
    Filed: June 14, 2017
    Date of Patent: November 1, 2022
    Inventors: Aya Jakobovits, Orit Foord, Daulet Kadyl Satpayev, Mira Peled Kamar, Galit Denkberg, Yoram Reiter, Ilan Beer, Keren Sinik, Yael Teboul (Elbaz), Yael Shperber (Sery), Reut Erel Segal, Ravit Oren, Dror Shmuel Alishekevitz
  • METHODS FOR SELECTIVE IN VIVO EXPANSION OF GAMMA DELTA T-CELL POPULATIONS AND COMPOSITIONS THEREOF
    Publication number: 20220218747
    Abstract: The present invention relates to methods for the selective in vivo activation, expansion and/or maintenance of ?? T-cell population(s), compositions and admixtures thereof and methods for using the same as a therapeutic. Methods and compositions of the disclosure are useful in the treatment of various cancers, infectious diseases, and immune disorders.
    Type: Application
    Filed: December 3, 2019
    Publication date: July 14, 2022
    Inventors: Aya JAKOBOVITS, Daulet SATPAYEV, Orit FOORD, Yifeng Frank JING, Hui SHAO
  • ENGINEERED GAMMA DELTA T-CELLS
    Publication number: 20220160765
    Abstract: The present invention relates to engineered ?? T-cell(s) and methods for using the same as a therapeutic with a potent and selective ability to target an antigen of choice. Engineered ?? T-cells of the disclosure are useful in the treatment of various cancers, infectious diseases, and immune disorders. Also disclosed are methods for expanding engineered and non-engineered ?? T-cell(s) populations to therapeutically useful quantities. An engineered ?? T-cell of the disclosure can be a universal donor, and can be administered to a subject with any MHC haplotype.
    Type: Application
    Filed: October 4, 2021
    Publication date: May 26, 2022
    Inventors: Aya Jakobovits, Orit Foord, Andy An-deh Lin, Marianne Theresa Santaguida
  • Methods for selective expansion of ?? T-cell populations and compositions thereof
    Patent number: 11299708
    Abstract: The present invention relates to methods for the selective expansion of ?? T-cell population(s), compositions and admixtures thereof and methods for using the same as a therapeutic. Non-engineered and engineered, enriched ?? T-cell populations of the disclosure are useful in the treatment of various cancers, infectious diseases, and immune disorders.
    Type: Grant
    Filed: May 12, 2017
    Date of Patent: April 12, 2022
    Assignee: ADICET BIO, INC.
    Inventors: Aya Jakobovits, Orit Foord, Andy An-deh Lin, Marianne Theresa Santaguida, Radhika Chetan Desai, Yifeng Frank Jing, Daulet Kadyl Satpayev, Yan Li
  • Engineered ?? T-cells
    Patent number: 11135245
    Abstract: The present invention relates to engineered ?? T-cell(s) and methods for using the same as a therapeutic with a potent and selective ability to target an antigen of choice. Engineered ?? T-cells of the disclosure are useful in the treatment of various cancers, infectious diseases, and immune disorders. Also disclosed are methods for expanding engineered and non-engineered ?? T-cell(s) populations to therapeutically useful quantities. An engineered ?? T-cell of the disclosure can be a universal donor, and can be administered to a subject with any MHC haplotype.
    Type: Grant
    Filed: November 17, 2015
    Date of Patent: October 5, 2021
    Assignee: ADICET BIO, INC.
    Inventors: Aya Jakobovits, Orit Foord, Andy An-deh Lin, Marianne Theresa Santaguida
  • Light chain variable regions
    Patent number: 11033634
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Grant
    Filed: December 6, 2019
    Date of Patent: June 15, 2021
    Assignee: AbbVie Stemcentrx LLC
    Inventors: Robert A. Stull, Laura Saunders, Scott J. Dylla, Orit Foord, David Liu, Michael Torgov, Hui Shao
  • Anti-PTK7 antibodies and methods of use
    Patent number: 10836831
    Abstract: Anti-PTK7 modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat hyperproliferative disorders are provided.
    Type: Grant
    Filed: January 29, 2018
    Date of Patent: November 17, 2020
    Assignee: ABBVIE STEMCENTRX LLC
    Inventors: Orit Foord, Scott J. Dylla, Robert A. Stull, Alex Bankovich, Alexandra Leida Liana Lazetic, Jeffrey Bernstein
  • ANTIBODIES CAPABLE OF BINDING HLA-A2/TYRD IN AN HLA RESTRICTED MANNER AND USES THEREOF
    Publication number: 20200207858
    Abstract: Antibodies capable of binding HLA-A2/Tyrosinase (TyrD) in an HLA restricted manner are provided. Specifically, the antibodies are capable of binding HLA-A2/TyrD369-377 in an HLA restricted manner. Further provided are complementary determining region (CDR) sequences of heavy chain and light chain of antibodies, and methods of using the antibodies for the treatment of cancer.
    Type: Application
    Filed: June 14, 2017
    Publication date: July 2, 2020
    Inventors: Aya Jakobovits, Orit FOORD, Daulet Kadyl Satpayev, Mira Peled Kamar, Galit Denkberg, Yoram Reiter, Ilan Beer, Keren Sinik, Yael Teboul (Elbaz), Yael Shperber (Sery), Reut Erel Segal, Ravit Oren, Dror Shmuel Alishekevitz
  • ANTI SEZ6 ANTIBODIES AND METHODS OF USE
    Publication number: 20200181256
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Application
    Filed: December 12, 2019
    Publication date: June 11, 2020
    Applicant: ABBVIE STEMCENTRX LLC
    Inventors: LAURA SAUNDERS, SCOTT J. DYLLA, ORIT FOORD, ROBERT A. STULL, MICHAEL TORGOV, HUI SHAO, DAVID LIU
  • DLL3 MODULATORS AND METHODS OF USE
    Publication number: 20200138969
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Application
    Filed: December 6, 2019
    Publication date: May 7, 2020
    Applicant: ABBVIE STEMCENTRX LLC
    Inventors: Robert A. Stull, Laura Saunders, Scott J. Dylla, Orit Foord, David Liu, Michael Torgov, Hui Shao
  • ANTIBODIES DIRECTED TO THE DELETION MUTANTS OF EPIDERMAL GROWTH FACTOR RECEPTOR AND USES THEREOF
    Publication number: 20200062860
    Abstract: The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.
    Type: Application
    Filed: November 4, 2019
    Publication date: February 27, 2020
    Inventors: Richard F. Weber, Xiao Feng, Orit Foord, Larry L. Green, Jean M. Gudas, Bruce A. Keyt, Ying Liu, Palaniswami Rathanaswami, Robert Raya, Xiao Dong Yang, Jose R.F. Corvalan, Ian Foltz, Xiao-Chi Jia, Jaspal Singh Kang, Chadwick Terence King, Scott L. Klakamp, Qiaojuan Jane Su
  • Anti SEZ6 antibodies and methods of use
    Patent number: 10533051
    Abstract: Provided are novel seizure related 6 (SEZ6) modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders.
    Type: Grant
    Filed: June 5, 2017
    Date of Patent: January 14, 2020
    Assignee: ABBVIE STEMCENTRX LLC
    Inventors: Laura Saunders, Scott J. Dylla, Orit Foord, Robert A. Stull, Michael Torgov, Hui Shao, David Liu
  • Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
    Patent number: 10508153
    Abstract: The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.
    Type: Grant
    Filed: June 18, 2015
    Date of Patent: December 17, 2019
    Assignee: Amgen Fremont Inc.
    Inventors: Richard F. Weber, Xiao Feng, Orit Foord, Larry L. Green, Jean M. Gudas, Bruce A. Keyt, Ying Liu, Palaniswami Rathanaswami, Robert Raya, Xiao Dong Yang, Jose R. F. Corvalan, Ian Foltz, Xiao-Chi Jia, Jaspal Singh Kang, Chadwick Terence King, Scott L. Klakamp, Qiaojuan Jane Su
  • DLL3 MODULATORS AND METHODS OF USE
    Publication number: 20190247510
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Application
    Filed: April 12, 2019
    Publication date: August 15, 2019
    Applicant: ABBVIE STEMCENTRX LLC
    Inventors: ROBERT A. STULL, LAURA SAUNDERS, SCOTT J. DYLLA, ORIT FOORD, DAVID LIU, MICHAEL TORGOV, HUI SHAO
  • METHODS FOR SELECTIVE EXPANSION OF GAMMA DELTA T-CELL POPULATIONS AND COMPOSITIONS THEREOF
    Publication number: 20190119634
    Abstract: The present invention relates to methods for the selective expansion of ?? T-cell population(s), compositions and ad-mixtures thereof and methods for using the same as a therapeutic. Non-engineered and engineered, enriched ?? T-cell populations of the disclosure are useful in the treatment of various cancers, infectious diseases, and immune disorders.
    Type: Application
    Filed: May 12, 2017
    Publication date: April 25, 2019
    Inventors: Aya Jakobovits, Orit Foord, Andy An-deh Lin, Marianne Theresa Santaguida, Radhika Chetan Desai, Yifeng Frank Jing, Daulet Kadyl Satpayev, Yan Li